Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
This article was originally published in The Pink Sheet Daily
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug's profile.
You may also be interested in...
Approval in very rare medullary thyroid cancer marks an important milestone for Exelixis’ Cometriq (cabozantinib), which is being positioned for multiple cancers. The company will need only five sales reps for the thyroid cancer market and plans to launch in late January 2013 at the price of $9,900 per 28 days.
The results from the event-driven pivotal trial of Exelixis Inc.’s cabozantinib in medullary thyroid cancer will be delayed by three more months, but there is a good chance for a positive outcome.
Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks
Novel adaptive randomized discontinuation design tested cabozantinib in nine tumor types, isolated best opportunities faster than traditional randomization.